Fig. 2From: Characteristics of safety information obtained from postmarketing observational studies for re-examination in JapanScatter plot of the adverse reaction rate in clinical studies for NDA (ARR-NDA) and the adverse reaction rate in PMI studies (ARR-PMI) (45 drug products, 48 sets). Vertical axis ARR-NDA adverse reaction rate in clinical studies for NDA. Horizontal axis ARR-PMI adverse reaction rate in postmarketing intervention studiesBack to article page